{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:13:04Z","timestamp":1789708384656,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114163","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:19:43Z","timestamp":1643483983000},"page":"114163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors"],"prefix":"10.1016","volume":"231","author":[{"given":"L\u00e1szl\u00f3","family":"Petri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"\u00c1br\u00e1nyi-Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8988-9787","authenticated-orcid":false,"given":"Darius","family":"Vagrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Imre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolett","family":"Varr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"M\u00e1ndity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"R\u00e1cz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Wittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estilla Zs\u00f3fia","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fcnde","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy Mikl\u00f3s","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejmech.2022.114163_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114163_bib2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/carcin\/bgs216","article-title":"Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research","volume":"33","author":"Singh","year":"2012","journal-title":"Carcinogenesis"},{"issue":"43","key":"10.1016\/j.ejmech.2022.114163_bib3","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114163_bib4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cmdc.201900107","article-title":"Covalent inhibition in drug discovery","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114163_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"21","key":"10.1016\/j.ejmech.2022.114163_bib6","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2174\/1568026619666191011163410","article-title":"Targeting protein-protein interaction with covalent small-molecule inhibitors","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010814-124401","article-title":"The design of covalent allosteric drugs","volume":"55","author":"Nussinov","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114163_bib8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molmed.2020.01.004","article-title":"Transcription factor inhibition: lessons learned and emerging targets","volume":"26","author":"Chen","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114163_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10555-020-09911-9","article-title":"Small molecule inhibitors of RAS proteins with oncogenic mutations","volume":"39","author":"Orgov\u00e1n","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114163_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0968-0004(02)02169-2","article-title":"Intrinsically unstructured proteins","volume":"27","author":"Tompa","year":"2002","journal-title":"Trends Biochem. Sci."},{"issue":"13","key":"10.1016\/j.ejmech.2022.114163_bib11","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/cr400525m","article-title":"Classification of intrinsically disordered regions and proteins","volume":"114","author":"van der Lee","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2022.114163_bib12","series-title":"Targeting an Intrinsically Disordered Protein by Covalent Modification","first-page":"835","author":"Nguyen","year":"2020"},{"issue":"7","key":"10.1016\/j.ejmech.2022.114163_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","article-title":"A\u00a0brief overview of tauopathy: causes, consequences, and therapeutic strategies","volume":"38","author":"Orr","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114163_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2022.114163_bib15","first-page":"1141","article-title":"Tau protein in neurodegenerative diseases - a review","volume":"58","author":"P\u00eer\u015fcoveanu","year":"2017","journal-title":"Rom. J. Morphol. Embryol."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4161\/pri.1.1.4055","article-title":"Tau aggregation in Alzheimer's disease","volume":"1","author":"Lippens","year":"2007","journal-title":"Prion"},{"issue":"47","key":"10.1016\/j.ejmech.2022.114163_bib17","doi-asserted-by":"crossref","first-page":"40638","DOI":"10.1074\/jbc.M111.271320","article-title":"Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation","volume":"286","author":"Tortosa","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"51","key":"10.1016\/j.ejmech.2022.114163_bib18","doi-asserted-by":"crossref","first-page":"48165","DOI":"10.1074\/jbc.M105196200","article-title":"Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local \u03b2-structure","volume":"276","author":"von Bergen","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114163_bib19","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","article-title":"Assembly of tau protein into alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming Beta structure","volume":"97","author":"von Bergen","year":"2000","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"32","key":"10.1016\/j.ejmech.2022.114163_bib20","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1021\/bi00198a017","article-title":"Domains of tau protein and interactions with microtubules","volume":"33","author":"Gustke","year":"1994","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.ejmech.2022.114163_bib21","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.3390\/ijms21155257","article-title":"Exploring IDP\u2013ligand interactions: tau K18 as a test case","volume":"21","author":"Vagrys","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"32","key":"10.1016\/j.ejmech.2022.114163_bib22","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1021\/bi00198a017","article-title":"Domains of tau protein and interactions with microtubules","volume":"33","author":"Gustke","year":"1994","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.ejmech.2022.114163_bib23","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/bi400240c","article-title":"Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid","volume":"52","author":"Yao","year":"2013","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.ejmech.2022.114163_bib24","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm3017317","article-title":"Progress and developments in tau aggregation inhibitors for alzheimer disease","volume":"56","author":"Bulic","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114163_bib25","series-title":"Two Targets for Dementia","first-page":"1","author":"Silva","year":"2020"},{"issue":"21","key":"10.1016\/j.ejmech.2022.114163_bib26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acs.biochem.1c00111","article-title":"Fungally derived isoquinoline demonstrates inducer-specific tau aggregation inhibition","volume":"60","author":"Ingham","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114163_bib27","doi-asserted-by":"crossref","first-page":"113209","DOI":"10.1016\/j.ejmech.2021.113209","article-title":"Amyloid-\u03b2 and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review","volume":"214","author":"Malafaia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0033-1360180","article-title":"Inhibition of tau aggregation by three Aspergillus nidulans secondary metabolites: 2,\u03c9-dihydroxyemodin, asperthecin, and asperbenzaldehyde","volume":"80","author":"Paranjape","year":"2014","journal-title":"Planta Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib29","doi-asserted-by":"crossref","first-page":"10216","DOI":"10.1038\/ncomms10216","article-title":"Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups","volume":"6","author":"Soeda","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114163_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/13506129.2014.929103","article-title":"Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking","volume":"21","author":"Haque","year":"2014","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/JAD-122113","article-title":"Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis","volume":"36","author":"George","year":"2013","journal-title":"J.\u00a0Alzheim. Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114163_bib32","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.3390\/molecules26123760","article-title":"The fumarprotocetraric acid inhibits tau covalently, avoiding cytotoxicity of aggregates in cells","volume":"26","author":"Gonz\u00e1lez","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.ejmech.2022.114163_bib33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/brainsci10110858","article-title":"Pharmacological modulators of tau aggregation and spreading","volume":"10","author":"Dominguez-Meijide","year":"2020","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cmdc.201500469","article-title":"Designing irreversible inhibitors-worth the effort?","volume":"11","author":"Gonz\u00e1lez-Bello","year":"2016","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114163_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/jm800498e","article-title":"Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins","volume":"52","author":"Smith","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2022.114163_bib36","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849 , a covalent KRAS G12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"issue":"7325","key":"10.1016\/j.ejmech.2022.114163_bib37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nature09472","article-title":"Quantitative reactivity profiling predicts functional cysteines in proteomes","volume":"468","author":"Weerapana","year":"2010","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.ejmech.2022.114163_bib38","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1021\/acs.biochem.7b00271","article-title":"Expanding the scope of electrophiles capable of targeting K-ras oncogenes","volume":"56","author":"McGregor","year":"2017","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.ejmech.2022.114163_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/c2np20012k","article-title":"Electrophilic natural products and their biological targets","volume":"29","author":"Gersch","year":"2012","journal-title":"Nat. Prod. Rep."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114163_bib40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/bioinformatics\/btw801","article-title":"CBinderDB: a covalent binding agent database","volume":"33","author":"Du","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2022.114163_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A\u00a0road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"\u00c1br\u00e1nyi-Balogh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114163_bib42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.drudis.2020.03.016","article-title":"Covalent fragment libraries in drug discovery","volume":"25","author":"Keeley","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114163_bib43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cbic.202000700","article-title":"Assessment of tractable cysteines for covalent targeting by screening covalent fragments","volume":"22","author":"Petri","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2022.114163_bib44","doi-asserted-by":"crossref","first-page":"112836","DOI":"10.1016\/j.ejmech.2020.112836","article-title":"An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases","volume":"207","author":"Petri","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"36","key":"10.1016\/j.ejmech.2022.114163_bib45","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1039\/C8CC01485J","article-title":"Cysteine-reactive probes and their use in chemical proteomics","volume":"54","author":"Hoch","year":"2018","journal-title":"Chem. Commun."},{"issue":"48","key":"10.1016\/j.ejmech.2022.114163_bib46","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1002\/anie.200704051","article-title":"Rhodanine-based tau aggregation inhibitors in cell models of tauopathy","volume":"46","author":"Bulic","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"issue":"7752","key":"10.1016\/j.ejmech.2022.114163_bib47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41586-019-1026-5","article-title":"Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules","volume":"568","author":"Falcon","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114163_bib48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nchem.2889","article-title":"Structure-based inhibitors of tau aggregation","volume":"10","author":"Seidler","year":"2018","journal-title":"Nat. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/bbrc.2001.5116","article-title":"Role of cysteine-291 and cysteine-322 in the polymerization of human tau into alzheimer-like filaments","volume":"285","author":"Bhattacharya","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"48","key":"10.1016\/j.ejmech.2022.114163_bib50","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1002\/anie.200704051","article-title":"Rhodanine-based tau aggregation inhibitors in cell models of tauopathy","volume":"46","author":"Bulic","year":"2007","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114163_bib51","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3390\/ijms19092677","article-title":"Targeting amyloid aggregation: an overview of strategies and mechanisms","volume":"19","author":"Giorgetti","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114163_bib52","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114163_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/protein\/14.8.529","article-title":"Design of the linkers which effectively separate domains of a bifunctional fusion protein","volume":"14","author":"Arai","year":"2001","journal-title":"Protein Eng. Des. Sel."},{"issue":"9","key":"10.1016\/j.ejmech.2022.114163_bib54","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.bioconjchem.6b00316","article-title":"Structural characterization of cross-linked species in trastuzumab emtansine (kadcyla)","volume":"27","author":"Chen","year":"2016","journal-title":"Bioconjugate Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pep.2008.04.013","article-title":"Increasing the homogeneity, stability and activity of human serum albumin and interferon-a2b fusion protein by linker engineering","volume":"61","author":"Zhao","year":"2008","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejmech.2022.114163_bib56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1039\/C39850000165","article-title":"Solid phase peptide synthesis using N \u03b1 -fluorenylmethoxycarbonylamino acid pentafluorophenyl esters","volume":"3","author":"Atherton","year":"1985","journal-title":"J.\u00a0Chem. Soc., Chem. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114163_bib57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nchem.2889","article-title":"Structure-based inhibitors of tau aggregation","volume":"10","author":"Seidler","year":"2018","journal-title":"Nat. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib58","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1038\/ncomms8025","article-title":"A\u00a0mechanistic model of tau amyloid aggregation based on direct observation of oligomers","volume":"6","author":"Shammas","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2017.1304905","article-title":"ThT 101: a primer on the use of Thioflavin T to investigate amyloid formation","volume":"24","author":"Gade Malmos","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114163_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","article-title":"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding","volume":"11","author":"Biernat","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.ejmech.2022.114163_bib62","series-title":"Analyzing Tau Aggregation with Electron Microscopy","first-page":"101","author":"Huseby","year":"2016"},{"issue":"24","key":"10.1016\/j.ejmech.2022.114163_bib63","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1021\/jm401251p","article-title":"Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis","volume":"56","author":"Al-Riyami","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114163_bib64","series-title":"\u03c0-Deficient 2-(Arylsulfonyl)Ethyl Esters as Protecting Groups for Carboxylic Acids","author":"Alonso","year":"2003"},{"issue":"9","key":"10.1016\/j.ejmech.2022.114163_bib65","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/molecules25092058","article-title":"Differential proliferation effect of the newly synthesized valine, tyrosine and tryptophan\u2013naphthoquinones in immortal and tumorigenic cervical cell lines","volume":"25","author":"C\u00f3rdova-Rivas","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114163_bib66","series-title":"Verfahren Zur Herstellung von AEthensulfarylamiden","first-page":"DE832149","author":"Friedrich","year":"1952"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:37:56Z","timestamp":1759329476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":65,"alternative-id":["S0223523422000654"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114163","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114163"}}